“We expect to deliver a very strong year of adjusted EPS growth in 2025.”

In context

“han 2024. We expect market growth will be slightly positive for the year, improving as the year progresses. With this market context and a very strong share gain, we expect organic growth for 2025 to be in the range of 3% to 4%. Now as I commented earlier, this includes a 1% headwind from the remainder of the pandemic runoff, largely in our clinical research business. So the underlying total company growth is strong. Turning to FX. Given recent changes in rates, we're assuming there will be a headwind from revenue from FX in 2025 of approximately $650 million or 1.5 points. Putting all this together, our top line guidance assumes a 1.5% to 2.5% increase in reported revenue dollars and a 3% to 4% increase in organic revenue. This is a strong step-up from 2024. Moving on to the bottom line. We expect to deliver a very strong year of adjusted EPS growth in 2025. The cost actions we took over the past couple of years are enabling very accretive pull-through on the incremental dollars of revenue growth, and we will continue to use the PPI Business System to drive productivity and actively manage our cost base. This will enable very strong adjusted operating margin expansion of approximately 90 basis points. Below the line, we're effectively managing our debt and cash positions and taking advantage of great interest rates from cash deposits. And all of this will enable us to deliver adjusted EPS in the range of $23.10 and $23.50, which is a very strong 6% to 8% growth for the year. In terms of potential changes in the macro environment, our guidance is assumed to cover the impact of modest policy changes. And then to help you with your modeling, her”